Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit. DalCor is currently conducting the dal-GenE study, a Phase 3 precision medicine cardiovascular o...
DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit. DalCor is currently conducting the dal-GenE study, a Phase 3 precision medicine cardiovascular outcomes trial to determine the efficacy of dalcetrapib in a genetically defined population with cardiovascular disease. The trial has enrolled 6,150 patients post-acute coronary syndrome (ACS).

List your booth number for exhibitions, ask us